Industry/FDA Line Extension Studies Suggested By OTC Division’s Rosebraugh
This article was originally published in The Tan Sheet
Executive Summary
The industry should partner with the FDA on studies evaluating whether OTC drug line extensions create consumer confusion, according to OTC Division Deputy Director Curtis Rosebraugh, MD
You may also be interested in...
FDA’s Rosebraugh Says OTC Labeling Studies Should Be More Rigorous
OTC drug manufacturers and FDA should collaborate to raise the quality of actual use and label comprehension studies to the level of clinical trials, according to OTC Drug Division Deputy Director Curtis Rosebraugh, MD
OTC Line Extension Restrictions Would Cause Consumer Confusion – CHPA
Restricting OTC brand name line extensions would lead to consumer confusion and fewer new product introductions, according to July 9 1comments submitted by the Consumer Healthcare Products Association
Drug Names Tentatively Accepted As Trademarks Could Be Placed On Internet
FDA is thinking of making tentatively accepted drug trade names viewable on the Internet